# An epidemiOlogy Study to deteRmine the Prevalence of EGFR (Epidermal Growth Factor Receptor) muTations in RUSsian Patients With Advanced NSCLC (Non-Small Cell Lung Cancer).

> **NCT02321046** · — · COMPLETED · sponsor: **AstraZeneca** · enrollment: 26 (actual)

## Conditions studied

- Non-Small Cell Lung Cancer

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT02321046
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2015-09-02
- **Primary completion:** 2019-06-28
- **Final completion:** 2019-06-28
- **Target enrollment:** 26 (ACTUAL)
- **Last updated:** 2020-06-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02321046

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02321046, "An epidemiOlogy Study to deteRmine the Prevalence of EGFR (Epidermal Growth Factor Receptor) muTations in RUSsian Patients With Advanced NSCLC (Non-Small Cell Lung Cancer).". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT02321046. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*